Published in Bone Marrow Transplant on June 05, 2017
International uniform response criteria for multiple myeloma. Leukemia (2006) 17.78
Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia (2008) 8.85
Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science (1999) 6.02
Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood (1995) 5.34
IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol (1997) 4.52
Ipilimumab for Patients with Relapse after Allogeneic Transplantation. N Engl J Med (2016) 1.88
Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy. Immunol Rev (1997) 1.74
Dysfunctional T regulatory cells in multiple myeloma. Blood (2005) 1.72
Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol (2007) 1.69
Clinical use of dendritic cells for cancer therapy. Lancet Oncol (2014) 1.63
PD-1/PD-L1 interactions contribute to functional T-cell impairment in patients who relapse with cancer after allogeneic stem cell transplantation. Cancer Res (2011) 1.24
siRNA silencing of PD-L1 and PD-L2 on dendritic cells augments expansion and function of minor histocompatibility antigen-specific CD8+ T cells. Blood (2010) 1.04
B and T lymphocyte attenuator mediates inhibition of tumor-reactive CD8+ T cells in patients after allogeneic stem cell transplantation. J Immunol (2012) 1.02
Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation. Cancer Immunol Immunother (2012) 1.01
Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation. Leuk Lymphoma (2006) 0.92
Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go. Front Immunol (2013) 0.90
Monitoring of minimal residual disease in multiple myeloma after allo-SCT: flow cytometry vs PCR-based techniques. Bone Marrow Transplant (2008) 0.87
T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of Immunotherapy. Cancer Immunol Res (2015) 0.86
Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma. Biol Blood Marrow Transplant (2009) 0.81
Sequential infusion of donor-derived dendritic cells with donor lymphocyte infusion for relapsed hematologic cancers after allogeneic hematopoietic stem cell transplantation. Am J Hematol (2014) 0.80
Induction of multiple myeloma-reactive T cells during post-transplantation immunotherapy with donor lymphocytes and recipient DCs. Bone Marrow Transplant (2012) 0.79
Bone marrow microenvironmental CD4 + and CD8 + lymphocyte infiltration patterns define overall- and progression free survival in standard risk multiple myeloma - an analysis from the Austrian Myeloma Registry. Leuk Lymphoma (2015) 0.78
Efficacy of host-dendritic cell vaccinations with or without minor histocompatibility antigen loading, combined with donor lymphocyte infusion in multiple myeloma patients. Bone Marrow Transplant (2016) 0.78
Multiple myeloma: altered CD4/CD8 ratio in bone marrow. Haematologica (1990) 0.76
Molecular typing methods for minor histocompatibility antigens. Methods Mol Biol (2014) 0.76
T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. J Hematol Oncol (2016) 0.75
Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation. Bone Marrow Transplant (2014) 1.28
Biomarker profiling of steroid-resistant acute GVHD in patients after infusion of mesenchymal stromal cells. Leukemia (2015) 0.82
Myeloablative T cell-depleted alloSCT with early sequential prophylactic donor lymphocyte infusion is an efficient and safe post-remission treatment for adult ALL. Bone Marrow Transplant (2013) 0.82
Efficacy of host-dendritic cell vaccinations with or without minor histocompatibility antigen loading, combined with donor lymphocyte infusion in multiple myeloma patients. Bone Marrow Transplant (2016) 0.78
The impact of circulating suppressor cells in multiple myeloma patients on clinical outcome of DLIs. Bone Marrow Transplant (2015) 0.75
Plastic CD34 and CD38 expression in adult B-cell precursor acute lymphoblastic leukemia explains ambiguity of leukemia-initiating stem cell populations. Leukemia (2016) 0.75
An activating mutation of GNB1 is associated with resistance to tyrosine kinase inhibitors in ETV6-ABL1-positive leukemia. Oncogene (2017) 0.75
Donor T-cell responses and disease progression patterns of multiple myeloma. Bone Marrow Transplant (2017) 0.75
Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Int J Lab Hematol (2016) 0.75
Functionally active NKG2A-expressing natural killer cells are elevated in rheumatoid arthritis patients compared to psoriatic arthritis patients and healthy donors. Clin Exp Rheumatol (2015) 0.75